Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001469802 | SCV001673891 | likely benign | not provided | 2024-02-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002447248 | SCV002734659 | likely benign | Nephrolithiasis/nephrocalcinosis | 2021-12-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV001279918 | SCV002799293 | likely benign | Primary hyperoxaluria, type II | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001279918 | SCV001467055 | uncertain significance | Primary hyperoxaluria, type II | 2020-08-14 | no assertion criteria provided | clinical testing |